Drug intelligence / Profile preview

CANNEFF SUP

Development stage: Unknown
Lead developer: CB21 Pharma
Modality: Small Molecules
Administration: Rectal

Overview

CANNEFF SUP is a CE-certified Class IIa medical device developed by CB21 Pharma for the treatment of various proctological conditions. It is a rectal suppository containing cannabidiol (CBD) as the active ingredient. The device is indicated to support the healing process of the anorectal canal following proctological surgeries and for the management of internal and external hemorrhoids, proctitis, cryptitis, anal fissures, and perianal fistulas. It works by delivering CBD locally to the affected anorectal tissues. The product is manufactured in an EU GMP-compliant facility and is available over-the-counter in Europe.

Brand names: CANNEFF SUPCANNEFF
Other names: CANNEFF rectal suppository

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on CANNEFF SUP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CANNEFF SUP.

Explore the full profile